Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for the Preventive Treatment of Menstrual Migraine
NCT06806293Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of atogepant in menstrual migraine, sponsored by AbbVie Inc.. Started Feb 2025; status: active, not recruiting.
02
Drugs
atogepant
03
Conditions
menstrual migraine
Beyond the preview
Go deeper on NCT06806293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806293.